HOME › Top Market Reports › Biomarkers Market Discovery Technologies (Proteomics, Genomics, Imaging, Bioinformatics), Applications (Drug Discovery, Personalized Medicine, Molecular Diagnostics) & Indications (Cancer, Cardiovascular & Neural) - Global Trends & Forecasts (2011 – 2020)

Biomarkers Market Discovery Technologies (Proteomics, Genomics, Imaging, Bioinformatics), Applications (Drug Discovery, Personalized Medicine, Molecular Diagnostics) & Indications (Cancer, Cardiovascular & Neural) - Global Trends & Forecasts (2011 – 2020)

By: marketsandmarkets.com
Publishing Date: January 2012
Report Code: BT 1033

A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic response to a therapeutic intervention. Biomarkers are classified in different ways based on different parameters such as on the basis of their application, their characteristics and on their usage in decision making in early drug development. With drug development facing challenges from ever increasing cost of developing drugs and rise in the failure rate for drugs in phase II and III clinical trials, biomarkers are being employed on large scale by pharmaceutical companies to overcome these challenges. Also the advent of personalized medicine and companion diagnostics is witnessing a strong presence of use of biomarkers and holds to be a big opportunity for the overall biomarker market.

The global biomarker market is also growing due to emergence of several new companies, providing advanced technology platforms in areas such as bioinformatics, genomics, metabolomics, transcriptomics, proteomics, and pharmacogenomics. Scientific progress in these areas likely to be a key driver for further biomarker research to improve sample throughputs, enhance detection levels, and generate multiple biomarker panels with increased utility in diagnostics, preclinical research, clinical trials and product commercialization.

This report studies the global biomarker market divided into global discovery technologies market, global application market across major indications which is given as a different segment; Global biomarker indication market over the forecast period (2011-2020). The global biomarker market is valued at $13.16 billion in 2011 growing at a steady pace of CAGR 14.40% to reach $25.79 billion by 2016. The biomarker discovery technology market is the major contributor of this market followed by the application market. Oncology is seen to be the largest indication in terms of revenue but cardiology is the fastest growing indication with a CAGR of 16.24% from 2011 to 2016. North America is leading the market followed by Europe and Asia is the fastest growing region due to high adoption rate of high throughput technologies for biomarker discovery and rapid growth of IT industry in this region.

Players are implementing various growth strategies in the market to gain competitive edge. New products launch, agreements and collaborations, partnerships, joint ventures, mergers and acquisitions, were some of the major strategies adopted by the players during the study period between January 2009 and December 2011. Our research indicates that agreements, partnerships, collaborations, and new joint ventures form a major growth strategy in the Global Biomarker Market accounting for a 42% share in this market.

Scope of the report

This Biomarkers Market research report categorizes on the basis of discovery technologies and application market across major indications; forecasting revenues and analyzing trends in each of the following submarkets:

The report categorizes the global biomarker market as follows:

Discovery technologies (Omics technologies comprising genomics, proteomics, metabolomics, transcriptomics and epigenomics; imaging technologies comprising PET, SPECT, CT, MRI, ultrasound, and bioinformatics)
Services market (Assay production and development, biomarker testing, and biomarker validation)
Applications market (drug development and discovery, personalized medicine, and molecular diagnostics)
Indications (Oncology, cardiology, neurology, and others)

On the basis of geography:

North America
Europe
Asia
ROW

In addition to market data on the submarkets of the global biomarker market, each section of the report will identify and analyze the market trends, opportunities, and the factors driving or inhibiting market growth. The report will also draw a competitive landscape, in which it will profile 40 key market players.

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
      1.4.1 MARKET SIZE
      1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES
      1.4.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 DEFINITION OF BIOMARKERS
3.2 BIOMARKERS & ITS TYPES
3.3 BIOMARKERS MARKET
      3.3.1 MARKET SEGMENTATION
      3.3.2 CHALLENGES & OPPORTUNITIES
            3.3.2.1 Challenges
                    3.3.2.1.1 Variability
                    3.3.2.1.2 Ethical considerations & acceptability
            3.3.2.2 Opportunities
                    3.3.2.2.1 Personalized medicine
                    3.3.2.2.2 Companion diagnostics
      3.3.3 DRIVERS & RESTRAINTS
            3.3.3.1 Drivers
                    3.3.3.1.1 High demand boosts the growth of the biomarker market globally
                    3.3.3.1.2 Strategic collaborations lead to increasing applications in the market
                    3.3.3.1.3 Technological advances contribute to growth
                    3.3.3.1.4 The rising prevalence of the disease forms
                    3.3.3.1.5 FDA support for biomarker development
            3.3.3.2 Restraints
                    3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers
                    3.3.3.2.2 Biomarkers not a profitable market for small organizations
                    3.3.3.2.3 Sample collection & storage
                    3.3.3.2.4 Limited biomarker validation
                    3.3.3.2.5 Need for new R&D models with greater precision & flexibility

4 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES
4.1 INTRODUCTION
4.2 IMAGING TECHNOLOGIES FOR BIOMARKER DISCOVERY
      4.2.1 POSITRON EMISSION TOMOGRAPHY (PET)
      4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT)
      4.2.3 ULTRASOUND
      4.2.4 MAGNETIC RESONANCE IMAGING (MRI)
      4.2.5 COMPUTED TOMOGRAPHY (CT)
4.3 OMICS TECHNOLOGIES FOR BIOMARKER DISCOVERY
      4.3.1 PROTEOMICS
            4.3.1.1 Mass spectrometry
                    4.3.1.1.1 MALDI mass spectrometry
                    4.3.1.1.2 Imaging mass spectrometry
            4.3.1.2 2D Gel Electrophoresis
            4.3.1.3 Protein microarray technology
            4.3.1.4 Antibody array technology
            4.3.1.5 Peptide array technology
      4.3.2 GENOMICS
            4.3.2.1 Whole genome sequencing
            4.3.2.2 Genotyping
            4.3.2.3 Epigenetics
      4.3.3 TRANSCRIPTOMICS
            4.3.3.1 Microarrays
            4.3.3.2 Gene expression profiling
      4.3.4 METABOLOMICS
            4.3.4.1 Capillary electrophoresis
            4.3.4.2 Mass spectrometry based kits
            4.3.4.3 Nuclear Magnetic Resonance(NMR)
4.4 BIOINFORMATICS
      4.4.1 CLUSTER ANALYSIS
      4.4.2 STATISTICAL ANALYSIS
      4.4.3 CELL SIGNAL PATHWAYS
      4.4.4 COMPUTER AIDED DESIGN
      4.4.5 DATA MINING
      4.4.6 PROTEIN INTERACTION MAPS

5 SERVICES MARKET OF BIOMARKERS
5.1 INTRODUCTION
5.2 CLINICAL
      5.2.1 SAMPLE PREPARATION
      5.2.2 ASSAY DEVELOPMENT
      5.2.3 BIOMARKER VALIDATION & TESTING
            5.2.3.1 Feasibility Studies and choice of assay & biomarker
            5.2.3.2 Long lead time required for Biomarker Assay preparation
5.3 BIOINFORMATICS
      5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS

6 BIOMARKER APPLICATION MARKET
6.1 INTRODUCTION
6.2 DRUG DISCOVERY & DEVELOPMENT
      6.2.1 CLINICAL TRIALS
            6.2.1.1 Preclinical Development
            6.2.1.2 Phase I drug development
            6.2.1.3 Phase II drug development
            6.2.1.4 Phase III drug development
            6.2.1.5 Phase IV drug development
6.3 PERSONALIZED MEDICINE
6.4 MOLECULAR DIAGNOSTICS
      6.4.1 MOLECULAR DIAGNOSTICS IS A DYNAMIC & RAPIDLY BROADENING MARKET
      6.4.2 TRENDS IN THE DIAGNOSTICS MARKET
      6.4.3 CHALLENGES
            6.4.3.1 Nucleic acids pose a challenge to the molecular diagnostics field
            6.4.3.2 Molecular diagnostics market lacks a collaborated effort
      6.4.4 DRIVER
            6.4.4.1 Increase in the incidence of diseases spurs the growth of the diagnostics market
      6.4.5 RESTRAINT
            6.4.5.1 The “interest-information” restricts growth of molecular diagnostics
      6.4.6 MOLECULAR DIAGNOSTICS IN MAJOR INDICATIONS
            6.4.6.1 Oncology
            6.4.6.2 Cardiology
            6.4.6.3 Neurology
            6.4.6.4 Other treatment areas
      6.4.7 BIOMARKERS IN DIAGNOSTICS
      6.4.8 BENEFITS OF MOLECULAR DIAGNOSTICS

7 BIOMARKER INDICATION MARKET
7.1 INTRODUCTION
7.2 ONCOLOGY BIOMARKER MARKET
      7.2.1 ONCOLOGY BIOMARKER DISCOVERY MARKET
            7.2.1.1 Genomics
            7.2.1.2 Proteomics
            7.2.1.3 Metabolomics
            7.2.1.4 Transcriptomics
            7.2.1.5 Other Omics
            7.2.1.6 Imaging
      7.2.2 DRUG DISCOVERY & DEVELOPMENT
      7.2.3 CANCER TYPES
            7.2.3.1 Ovarian Cancer
            7.2.3.2 Breast Cancer
            7.2.3.3 Bladder Cancer
            7.2.3.4 Cervical Cancer
            7.2.3.5 Prostate Cancer
            7.2.3.6 Lung Cancer
            7.2.3.7 Colorectal Cancer
7.3 CARDIOLOGY BIOMARKERS MARKET
      7.3.1 CARDIOLOGY BIOMARKER DISCOVERY MARKET
            7.3.1.1 Genomics
            7.3.1.2 Proteomics
            7.3.1.3 Metabolomics
            7.3.1.4 Transcriptomics
            7.3.1.5 Imaging
            7.3.1.6 Bioinformatics
      7.3.2 DRUG DISCOVERY & DEVELOPMENT
      7.3.3 CARDIAC MARKERS, BY DISEASE TYPES
            7.3.3.1 Acute Coronary Syndrome
            7.3.3.2 Coronary artery disease
            7.3.3.3 Stroke
      7.3.4 CARDIOLOGY BIOMARKERS USED IN THE MARKET
7.4 NEUROLOGY BIOMARKER MARKET
      7.4.1 NEUROLOGY BIOMARKER DISCOVERY MARKET
            7.4.1.1 Omics technologies
            7.4.1.2 Imaging Technologies
      7.4.2 DRUG DISCOVERY & DEVELOPMENT
      7.4.3 DISEASE TYPES
            7.4.3.1 Alzheimer’s disease
            7.4.3.2 Parkinson’s disease
            7.4.3.3 Multiple sclerosis
            7.4.3.4 Schizophrenia
            7.4.3.5 Amyotrophic Lateral Sclerosis
            7.4.3.6 Epilepsy
7.5 OTHER INDICATIONS BIOMARKER MARKET
      7.5.1 OTHER INDICATION BIOMARKER DISCOVERY MARKET
            7.5.1.1 Omics technologies
            7.5.1.2 Imaging technologies
      7.5.2 DRUG DISCOVERY & DEVELOPMENT
7.6 DISEASE TYPES
      7.6.1 HIV
            7.6.1.1 Immunological & Virological Markers in HIV Infection
7.7 RENAL FAILURE
7.8 ARTHRITIS
7.9 TUBERCULOSIS
7.10 DIABETES

8 GEOGRAPHICAL ANALYSIS
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA
8.5 ROW

9 COMPETITIVE LANDSCAPE
9.1 KEY STRATEGIES
9.2 MERGERS & ACQUISITIONS
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
9.4 NEW PRODUCTS LAUNCH
9.5 OTHER DEVELOPMENTS

10 COMPANY PROFILES
10.1 ABBOTT LABORATORIES
      10.1.1 OVERVIEW
      10.1.2 FINANCIALS
      10.1.3 PRODUCTS & SERVICES
      10.1.4 STRATEGY
      10.1.5 DEVELOPMENTS
10.2 ABCODIA LTD
      10.2.1 OVERVIEW
      10.2.2 FINANCIALS
      10.2.3 PRODUCTS & SERVICES
      10.2.4 STRATEGY
      10.2.5 DEVELOPMENTS
10.3 AFFYMETRIX INC
      10.3.1 OVERVIEW
      10.3.2 FINANCIALS
      10.3.3 PRODUCTS & SERVICES
      10.3.4 STRATEGY
      10.3.5 DEVELOPMENTS
10.4 AGILENT TECHNOLOGIES INC
      10.4.1 OVERVIEW
      10.4.2 FINANCIALS
      10.4.3 PRODUCTS & SERVICES
      10.4.4 STRATEGY
      10.4.5 DEVELOPMENTS
10.5 AMGEN INC
      10.5.1 OVERVIEW
      10.5.2 FINANCIALS
      10.5.3 PRODUCTS & SERVICES
      10.5.4 STRATEGY
      10.5.5 DEVELOPMENT
10.6 ASTRAZENECA PLC
      10.6.1 OVERVIEW
      10.6.2 FINANCIALS
      10.6.3 PRODUCTS & SERVICES
      10.6.4 STRATEGY
      10.6.5 DEVELOPMENTS
10.7 AUGUREX LIFE SCIENCES CORP
      10.7.1 OVERVIEW
      10.7.2 FINANCIALS
      10.7.3 PRODUCTS & SERVICES
      10.7.4 STRATEGY
      10.7.5 DEVELOPMENTS
10.8 AUSHON BIOSYSTEMS INC
      10.8.1 OVERVIEW
      10.8.2 FINANCIALS
      10.8.3 PRODUCTS & SERVICES
      10.8.4 STRATEGY
      10.8.5 DEVELOPMENTS
10.9 BAYER AG
      10.9.1 OVERVIEW
      10.9.2 FINANCIALS
      10.9.3 PRODUCTS & SERVICES
      10.9.4 STRATEGY
      10.9.5 DEVELOPMENTS
10.1 BECKMAN COULTER INC
      10.10.1 OVERVIEW
      10.10.2 FINANCIALS
      10.10.3 PRODUCTS & SERVICES
      10.10.4 STRATEGY
      10.10.5 DEVELOPMENTS
10.11 BGI
      10.11.1 OVERVIEW
      10.11.2 FINANCIALS
      10.11.3 PRODUCTS & SERVICES
      10.11.4 STRATEGY
      10.11.5 DEVELOPMENTS
10.12 BIOCRATES LIFE SCIENCES AG
      10.12.1 OVERVIEW
      10.12.2 FINANCIALS
      10.12.3 PRODUCTS & SERVICES
      10.12.4 STRATEGY
      10.12.5 DEVELOPMENTS
10.13 BIOMARKER STRATEGIES
      10.13.1 OVERVIEW
      10.13.2 FINANCIALS
      10.13.3 PRODUCTS & SERVICES
      10.13.4 STRATEGY
      10.13.5 DEVELOPMENTS
10.14 BIOSYSTEMS INTERNATIONAL
      10.14.1 OVERVIEW
      10.14.2 FINANCIALS
      10.14.3 PRODUCTS & SERVICES
      10.14.4 STRATEGY
      10.14.5 DEVELOPMENTS
10.15 BRISTOL-MYERS SQUIBB
      10.15.1 OVERVIEW
      10.15.2 FINANCIALS
      10.15.3 PRODUCTS & SERVICES
      10.15.4 STRATEGY
      10.15.5 DEVELOPMENTS
10.16 CRESCENDO BIOSCIENCE
      10.16.1 OVERVIEW
      10.16.2 FINANCIALS
      10.16.3 PRODUCTS & SERVICES
      10.16.4 STRATEGY
      10.16.5 DEVELOPMENTS
10.17 EISAI CO. LTD.
      10.17.1 OVERVIEW
      10.17.2 FINANCIALS
      10.17.3 PRODUCTS & SERVICES
      10.17.4 STRATEGY
      10.17.5 DEVELOPMENTS
10.18 EPIONTIS GMBH
      10.18.1 OVERVIEW
      10.18.2 FINANCIALS
      10.18.3 PRODUCTS & SERVICES
      10.18.4 DEVELOPMENTS
10.19 EPISTEM HOLDINGS PLC
      10.19.1 OVERVIEW
      10.19.2 FINANCIALS
      10.19.3 PRODUCTS & SERVICES
      10.19.4 STRATEGY
      10.19.5 DEVELOPMENTS
10.20 EUROGENTEC S.A.
      10.20.1 OVERVIEW
      10.20.2 FINANCIALS
      10.20.3 PRODUCTS & SERVICES
      10.20.4 STRATEGY
      10.20.5 DEVELOPMENTS
10.21 EVOTEC AG
      10.21.1 OVERVIEW
      10.21.2 FINANCIALS
      10.21.3 PRODUCTS & SERVICES
      10.21.4 STRATEGY
      10.21.5 DEVELOPMENTS
10.22 GLAXOSMITHKLINE PLC
      10.22.1 OVERVIEW
      10.22.2 FINANCIALS
      10.22.3 PRODUCTS & SERVICES
      10.22.4 STRATEGY
      10.22.5 DEVELOPMENTS
10.23 IPSEN
      10.23.1 OVERVIEW
      10.23.2 FINANCIALS
      10.23.3 PRODUCTS & SERVICES
      10.23.4 STRATEGY
      10.23.5 DEVELOPMENTS
10.24 JOHNSON & JOHNSON
      10.24.1 OVERVIEW
      10.24.2 FINANCIALS
      10.24.3 PRODUCTS & SERVICES
      10.24.4 STRATEGY
      10.24.5 DEVELOPMENTS
10.25 MERCK & CO.
      10.25.1 OVERVIEW
      10.25.2 FINANCIALS
      10.25.3 PRODUCTS & SERVICES
      10.25.4 STRATEGY
      10.25.5 DEVELOPMENTS
10.26 MICROMEDIC TECHNOLOGIES LTD
      10.26.1 OVERVIEW
      10.26.2 PRODUCTS & SERVICES
      10.26.3 STRATEGY
      10.26.4 DEVELOPMENTS
10.27 MYRIAD GENETICS INC
      10.27.1 OVERVIEW
      10.27.2 FINANCIALS
      10.27.3 PRODUCTS & SERVICES
      10.27.4 STRATEGY
      10.27.5 DEVELOPMENTS
10.28 NEXTGEN SCIENCES INC
      10.28.1 OVERVIEW
      10.28.2 FINANCIALS
      10.28.3 PRODUCTS & SERVICES
      10.28.4 STRATEGY
      10.28.5 DEVELOPMENTS
10.29 NOVARTIS INTERNATIONAL AG
      10.29.1 OVERVIEW
      10.29.2 FINANCIALS
      10.29.3 PRODUCTS & SERVICES
      10.29.4 STRATEGY
      10.29.5 DEVELOPMENTS
10.30 OCIMUM BIOSOLUTIONS LTD
      10.30.1 OVERVIEW
      10.30.2 FINANCIALS
      10.30.3 PRODUCTS & SERVICES
      10.30.4 STRATEGY
      10.30.5 DEVELOPMENTS
10.31 PFIZER INC
      10.31.1 OVERVIEW
      10.31.2 FINANCIALS
      10.31.3 PRODUCTS & SERVICES
      10.31.4 STRATEGY
      10.31.5 DEVELOPMENTS
10.32 PRONOTA NV
      10.32.1 OVERVIEW
      10.32.2 FINANCIALS
      10.32.3 PRODUCTS & SERVICES
      10.32.4 STRATEGY
      10.32.5 DEVELOPMENTS
10.33 QUINTILES TRANSNATIONAL CORPORATION
      10.33.1 OVERVIEW
      10.33.2 FINANCIALS
      10.33.3 PRODUCTS & SERVICES
      10.33.4 STRATEGY
      10.33.5 DEVELOPMENTS
10.34 QIAGEN NV
      10.34.1 OVERVIEW
      10.34.2 FINANCIALS
      10.34.3 PRODUCTS & SERVICES
      10.34.4 STRATEGY
      10.34.5 DEVELOPMENTS
10.35 ROCHE DIAGNOSTICS LIMITED
      10.35.1 OVERVIEW
      10.35.2 FINANCIALS
      10.35.3 PRODUCTS & SERVICES
      10.35.4 STRATEGY
      10.35.5 DEVELOPMENT
10.36 SANOFI-AVENTIS
      10.36.1 OVERVIEW
      10.36.2 FINANCIALS
      10.36.3 PRODUCTS & SERVICES
      10.36.4 STRATEGY
      10.36.5 DEVELOPMENT
10.37 SIEMENS HEALTHCARE
      10.37.1 OVERVIEW
      10.37.2 FINANCIALS
      10.37.3 PRODUCTS & SERVICES
      10.37.4 STRATEGY
      10.37.5 DEVELOPMENTS
10.38 TRANS-HIT BIOMARKERS INC
      10.38.1 OVERVIEW
      10.38.2 FINANCIALS
      10.38.3 PRODUCTS & SERVICES
      10.38.4 STRATEGY
      10.38.5 DEVELOPMENTS
10.39 PACIFIC BIOMARKERS INC
      10.39.1 OVERVIEW
      10.39.2 FINANCIALS
      10.39.3 PRODUCTS & SERVICES
      10.39.4 STRATEGY
      10.39.5 DEVELOPMENTS
10.40 CAPRION PROTEOMICS INC.
      10.40.1 OVERVIEW
      10.40.2 FINANCIALS
      10.40.3 PRODUCTS & SERVICES
      10.40.4 STRATEGY
      10.40.5 DEVELOPMENTS
10.41 PROTEOME SCIENCES PLC
      10.41.1 OVERVIEW
      10.41.2 FINANCIALS
      10.41.3 PRODUCTS & SERVICES
      10.41.4 STRATEGY
      10.41.5 DEVELOPMENTS
10.42 VERMILLION INC
      10.42.1 OVERVIEW
      10.42.2 FINANCIALS
      10.42.3 PRODUCTS & SERVICES
      10.42.4 STRATEGY
      10.42.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 GLOBAL BIOMARKER MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 2 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 3 GLOBAL BIOMARKER DISCOVERY MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 4 BIOMARKER DISCOVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 5 GLOBAL BIOMARKER DISCOVERY MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 6 BIOMARKER IMAGING TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 7 GLOBAL BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 8 GLOBAL BIOMARKER OMICS TECHNOLOGIES MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 9 BIOMARKER OMICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 10 GLOBAL PROTEOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 11 GLOBAL GENOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 12 GLOBAL TRANSCRIPTOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 13 GLOBAL METABOLOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 14 GLOBAL BIOMARKER BIOINFORMATICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 15 BIOMARKER BIOINFORMATICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 16 GLOBAL BIOMARKER MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 17 GLOBAL BIOMARKER APPLICATION MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 18 BIOMARKER APPLICATION MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 19 GLOBAL BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 20 BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 21 GLOBAL BIOMARKER APPLICATION MARKET, BY PHASES IN DRUG DISCOVERY & DEVELOPMENT PROCESS, 2009 – 2020 ($MILLION)
TABLE 22 GLOBAL BIOMARKER PRECLINICAL STUDY MARKET, BY VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 23 GLOBAL BIOMARKER PHASE I MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 24 GLOBAL BIOMARKER PHASE II MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 25 GLOBAL BIOMARKER PHASE III MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 26 GLOBAL BIOMARKER PHASE IV MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 27 PERSONALIZED MEDICINE(PM) USING BIOMARKERS IN CURRENT DRUG LABELS
TABLE 28 GLOBAL BIOMARKER PERSONALIZED MEDICINE MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 29 BIOMARKER PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 32 GLOBAL BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 33 GLOBAL ONCOLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 34 GLOBAL ONCOLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 35 GLOBAL ONCOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 37 GLOBAL ONCOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 38 GLOBAL ONCOLOGY BIOMARKER MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 39 ONCOLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 40 GLOBAL CARDIOLOGY BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 41 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 42 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 43 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 44 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 45 GLOBAL CARDIOLOGY MARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 46 COMMONLY USED CARDIAC BIOMARKER TESTS
TABLE 47 BIOMARKER TESTS USED FOR PROGNOSIS
TABLE 48 CARDIAC MARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 49 GLOBAL NEUROLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 50 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 51 GLOBAL NEUROLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 52 GLOBAL NEUROLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 53 GLOBAL NEUROLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 54 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISEASE TYPES, 2009– 2020 ($MILLION)
TABLE 55 NEUROLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 56 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)
TABLE 57 GLOBAL OTHER INDICATIONS BIOMARKER MARKET REVENUE, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 58 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 59 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 60 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION)
TABLE 61 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 62 HIV BIOMARKERS
TABLE 63 RENAL BIOMARKERS
TABLE 64 OTHER INDICATIONS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)
TABLE 65 BIOMARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($BILLION)
TABLE 66 NORTH AMERICA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 67 NORTH AMERICA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 69 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 70 NORTH AMERICA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 71 NORTH AMERICA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 72 NORTH AMERICA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 73 NORTH AMERICA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 74 NORTH AMERICA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 75 NORTH AMERICA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 76 EUROPE: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 77 EUROPE: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 78 EUROPE: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 79 EUROPE: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 80 EUROPE: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 81 EUROPE: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 82 EUROPE: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 83 EUROPE: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 84 EUROPE: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 85 EUROPE: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 86 ASIA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 87 ASIA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 88 ASIA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 89 ASIA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 90 ASIA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 91 ASIA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 92 ASIA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 93 ASIA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 94 ASIA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 95 ASIA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 96 ROW: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 97 ROW: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 98 ROW: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)
TABLE 99 ROW: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION)
TABLE 100 ROW: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION)
TABLE 101 ROW: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)
TABLE 102 ROW: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)
TABLE 103 ROW: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 104 ROW: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)
TABLE 105 ROW: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)
TABLE 106 MERGERS & ACQUISITIONS (JANUARY 2009 – DECEMBER 2011)
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (JANUARY 2009 – DECEMBER 2011)
TABLE 108 NEW PRODUCTS LAUNCH (JANUARY 2009 – DECEMBER 2011)
TABLE 109 OTHER DEVELOPMENTS (JANUARY 2009 – DECEMBER 2011)
TABLE 110 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 111 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 112 ABBOTT LABORATORIES: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 113 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 114 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 115 AFFYMETRIX INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 116 AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 117 AGILENT TECHNOLOGIES INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 118 AGILENT TECHNOLOGIES INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 119 AMGEN INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 120 AMGEN INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 121 ASTRAZENECA PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 122 ASTRAZENECA PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 123 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 124 BAYER AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 125 BAYER AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 126 BAYER AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 127 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 128 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 129 BECKMAN COULTER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 130 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 131 BRISTOL-MYERS SQUIBB: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 132 BRISTOL-MYERS SQUIBB: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 133 EISAI CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 134 EISAI CO. LTD: TOTAL REVENUES, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 135 EISAI CO. LTD: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 136 EPISTEM HOLDINGS PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 137 EPISTEM HOLDINGS PLC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 138 EPISTEM HOLDINGS PLC: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 139 EVOTEC AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 140 EVOTEC AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 141 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2011 ($MILLION)
TABLE 142 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2011 ($MILLION)
TABLE 143 GLAXOSMITHKLINE PLC: REVENUE FOR PHARMACEUTICAL SEGMENT, BY GEOGRAPHY, 2008 – 2011 ($MILLION)
TABLE 144 IPSEN: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 145 IPSEN: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 146 IPSEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 147 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 148 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2008 -2010 ($MILLION)
TABLE 149 MEDICAL DEVICES & DIAGNOSTICS SEGMENT REVENUE, 2008 – 2010 ($MILLION)
TABLE 150 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 151 MERCK & CO: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 152 MERCK & CO: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 153 MERCK & CO: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 154 MYRIAD GENETICS INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 155 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 156 NEXTGEN GROUP PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 157 NEXTGEN GROUP PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 158 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 159 NOVARTIS INTERNATIONAL AG: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 160 NOVARTIS INTERNATIONAL AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 161 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 162 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 163 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 164 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 165 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 166 QIAGEN N.V.: GEOGRAPHIC REVENUES, 2008 – 2010 ($MILLION)
TABLE 167 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 168 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 169 SANOFI-AVENTIS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 170 SANOFI-AVENTIS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 171 SANOFI-AVENTIS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 172 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 173 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 174 SIEMENS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 175 PROTEOME SCIENCES PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 176 PROTEOME SCIENCES PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 177 VERMILLION INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 178 VERMILLION INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)


LIST OF FIGURES

FIGURE 1 OVERVIEW OF BIOMARKERS MARKET
FIGURE 2 LIFE CYCLE OF A BIOMARKER
FIGURE 3 BIOMARKER MARKET
FIGURE 4 LEVEL OF IMPACT OF CHALLENGES
FIGURE 5 BIOMARKER DISCOVERY PROCESS
FIGURE 6 BIOMARKER DISCOVERY MARKET, 2011
FIGURE 7 OMICS TECHNOLOGIES & THE CENTRAL DOGMA
FIGURE 8 BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2011
FIGURE 9 THE CENTRAL ROLE OF MASS SPECTROMETRY IN PROTEOMICS
FIGURE 10 BIOMARKER DISCOVERY USING 2-D DIGE & MS
FIGURE 11 TRANSCRIPTOMICS BIOMARKER DISCOVERY
FIGURE 12 BIOINFORMATICS MICROARRAY TOOLS
FIGURE 13 CLUSTER ANALYSIS OF OMICS DATA FOR BIOMARKER DISCOVERY
FIGURE 14 BIOMARKER SERVICES MARKET, BY SEGMENTS (%)
FIGURE 15 FLOW OF CLINICAL BIOMARKER SERVICES
FIGURE 16 DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 17 BIOMARKER DISCOVERY, BY INDICATIONS, 2011
FIGURE 18 KEY GROWTH STRATEGIES (JANUARY 2009 – DECEMBER 2011)

The U.S. National Institutes of Health (NIH) defines biomarkers as “physical, functional, or biochemical indicators of a physiological or disease process that have diagnostic and/or prognostic utility.” Biomarkers have great value in the pharmaceutical industry as they can be used to infer the Pharmacokinetics and pharmacodynamics. This market has potential for growth because these biomarkers are employed and utilized in all therapeutic areas and affects our ability to diagnose and monitor disease progression at early stage.

The global biomarker market is broadly segmented into biomarker discovery market, application market across major indications, which is given as a different chapter as biomarkers market by indications. The global biomarker market is valued at $13.16 billion in 2011 growing at a CAGR of 14.40% to reach $25.79 billion by 2016. Ethical consideration and acceptability is a major concern of biomarkers market. This market is expected to be driven by the technological advancement in biomarker discovery, strategic collaborations, and the rising prevalence of all disease forms.

Impact of Key Market Drivers & Restraints

Biomarkers Market

Source: MarketsandMarkets Analysis

Apart from this, FDA support for biomarker development also act as drivers for this market. Huge capital investment and high cost of biomarker validation are major concerns which weigh down the growth of the biomarker market.

Custom Market Research Services